Lloyd Dunlap
This person does not yet have a bio.
Articles by Lloyd Dunlap
| 3 min read
A
gap caused during DNA replication could result in cancer-causing mutations
| 3 min read
Rexahn progresses its Phase
2a clinical research in metastatic renal cell carcinoma
| 5 min read
Data from four posters include results of Phase 1 study, patient case report and
preclinical research
| 3 min read
DDNews speaks with Bill Barbo, senior vice president of global sales and marketing for Charles River Laboratories, about such things as his company’s
acquisition of WIL Research and the role Charles River is playing in advancing immunotherapy research
| 10+ min read
Key areas to be addressed at AACR annual meeting include immunotherapy,
epigenetics and newer techniques and tools such as CRISPR
| 3 min read
MedImmune and UCSF enter research collaboration aimed at respiratory conditions, inflammation and autoimmunity
| 4 min read
additional positive data from the CoDIFy Phase 2 clinical trial show
the narrow spectrum antibiotic ridinilazole preserves the gut microbiome in CDI patients while the standard of care, vancomycin, inflicts substantial and
long-lasting damage
| 4 min read
CoLucid Pharmaceuticals, Inc., is developing its lead product candidate, lasmiditan, for the acute treatment of migraine
| 5 min read
Onxeo acquires first-in-class, signal-interfering DNA molecule based on a
promising new approach in cancer treatment
| 3 min read
Company exploring potential to advance ANAVEX 2-73 into human clinical studies in rare disease indication
| 3 min read
Agreement
accelerates development of Adaptimmune’s lead T cell therapy targeting NY-ESO-1 toward pivotal trials
